Lv11
4 积分 2023-03-06 加入
Ivonescimab in advanced NSCLC: is progression-free survival enough, or are overall survival data also needed?
5小时前
已完结
The evolving immuno-angiogenic paradigm in NSCLC: lessons from ivonescimab
5小时前
已完结
Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis
8天前
已完结
Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis
8天前
已完结
Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys
1个月前
已完结
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
1个月前
已完结
Antibody Drug Conjugates for Cancer Therapy
1个月前
已完结
Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929
2个月前
已完结
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
3个月前
已完结
Carboplatin dosage: prospective evaluation of a simple formula based on renal function
4个月前
已完结
皖公网安备34019202002308
